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Magnetic resonance imaging (MRI) with molecular
probes offers the potential to monitor physiological
parameters with comparatively high spatial and
temporal resolution in living subjects. For detection
of intracellular analytes, construction of cell-perme-
able imaging agents remains a challenge. Here we
show that a porphyrin-based MRI molecular imaging
agent, Mn-(DPA-C2)2-TPPS3, effectively penetrates
cells and persistently stains living brain tissue in intra-
cranially injected rats. Chromogenicity of the probe
permitted direct visualization of its distribution by
histology, in addition toMRI.Distributionwasconcen-
trated in cell bodies after hippocampal infusion. Mn-
(DPA-C2)2-TPPS3 was designed to sense zinc ions,
and contrast enhancement was more pronounced in
the hippocampus, a zinc-rich brain region, than in
the caudate nucleus, which contains relatively little
labile Zn2+. Membrane permeability, optical activity,
andhigh relaxivityofporphyrin-basedcontrastagents
offer exceptional functionality for in vivo imaging.
INTRODUCTION
Molecular imaging of intracellular targets and processes using
magnetic resonance must rely on effective uptake of contrast
agents by cells in vivo. Small molecule MRI contrast agents are
typically based on highly polar, often charged, paramagnetic
metal chelates such as Gd-diethylenetriaminetetraacetic acid
(DTPA) or Gd-tetraazacyclododecanetetraacetic acid (DOTA),
which have intrinsically low transmembrane permeability
(Caravan et al., 1999). To reduce barriers against cellular uptake
of polar contrast agents, it has been possible to conjugate them
to distinct chemical moieties that promote intracellular internali-
zation. Most extensively explored have been so-called cell-
penetrating peptides (CPPs) (Derossi et al., 1994; Vives et al.,
1997), short polycationic amino acid sequences that transport
various molecular cargoes into cells (Fonseca et al., 2009).
Gd3+-containing small molecule MRI contrast agents conjugated
to CPPs are effectively internalized by cells in vitro (Allen andChemistry & Biology 17,Meade, 2003; Bhorade et al., 2000; Heckl et al., 2002; Prantner
et al., 2003). Further conjugation-based cell delivery approaches
have involved fusion of contrast agents to amphipathic moieties
(Endres et al., 2006; Sturzu et al., 2009) or thiol-reactive groups
(Digilio et al., 2009) that are thought to interact with plasma
membrane components. Incorporation of MRI contrast agents
into liposomes or carbon nanotubes also facilitates cell delivery
(Torchilin, 2007). Few of these approaches have been shown to
promote intracellular localization of paramagnetic contrast
agents in intact tissue, however.
An alternative approach to producing cell-permeable contrast
agents is to construct agents from paramagnetic platforms that
intrinsically favor transport into cells. Water soluble metallopor-
phyrins provide suitable building blocks for this purpose (Zhang
et al., 2007). A quintessential porphyrin-based MRI contrast
agent, Mn(III)-meso-tetrakis(4-sulfonatophenyl)porphyrin (Mn-
TPPS4), has high longitudinal (T1) magnetic resonance relaxivity
(Chen et al., 1984; Koenig et al., 1987) and localizes in tumors
(Fiel et al., 1987; Lyon et al., 1987; Ogan et al., 1987). There is
evidence that metalloporphyrin (Megnin et al., 1987) or
expanded porphyrin (Woodburn, 2001; Young et al., 1996)
agents penetrate cells under various circumstances, possibly
because of their hydrophobic surface area and charge delocal-
ization over the aromatic porphyrin ring. Imaging probes based
on porphyrins could be designed to target or sense analytes
using mechanisms applied previously in conjunction with DTPA
or DOTA-related chelates (Jasanoff, 2007).
As an initial test of the metalloporphyrin platform for molecular
imaging, we recently synthesized Mn-(DPA-C2)2-TPPS3 (Fig-
ure 1A), a Mn-TPPS4 analog containing dipicolylamine (DPA)
groups to bind labile Zn2+ ions (Zhang et al., 2007). Relatively
high, 200 mM concentrations of this probe incubated with
cultured cells produced robust contrast enhancements.
T1-weighted MRI signal increases in cell culture were more
pronounced for Mn-(DPA-C2)2-TPPS3 than for Mn-TPPS4, and
were greatest for the probe in the presence of 1 mM exogenous
Zn2+ ions. An inconsistency between zinc-dependent MRI
changes exhibited by Mn-(DPA-C2)2-TPPS3 in cells versus buffer
suggested that the cell culture results arose from differences in
the relative uptake efficiencies of zinc-complexed and uncom-
plexed forms of the molecule, rather than from zinc-dependent
effects on its relaxivity. Neither the extent of cellular uptake of
the probe nor its subcellular localization were directly measured
in this study, however.665–673, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 665
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Figure 1. MRI Contrast Enhanced by Injection of
Porphyrin Agents into Rat Hippocampus
(A) Structures of Mn-(DPA-C2)2-TPPS3 and Mn-TPPS4.
(B) Contrast enhancement in a representative animal, two
days after injection with Mn-(DPA-C2)2-TPPS3 into the left
hippocampus and Mn-TPPS4 into the opposite hemi-
sphere. T1-weighted MRI data were acquired with 75 3
75 3 300 mm voxels and TE/TR = 6/50 ms.
(C) Images from the animal in panel (B) obtained four and
ten days after injection, showing slowly fading image
enhancement near the Mn-(DPA-C2)2-TPPS3 infusion site.
(D) A graph of relative MRI signal as a function of time in
1.2 mm-radius spherical regions of interest (ROIs) around
the Mn-(DPA-C2)2-TPPS3 and Mn-TPPS4 injection loca-
tions. To compute relative MRI signal, the image intensity
in each hippocampal ROI was normalized by the signal
in uninjected control volumes positioned lateral to the
infusion sites. Error bars denote standard errors of the
mean (SEM) over 7 rats. See also Figure S1 (available
online).
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In Vivo MRI with a Porphyrin-Based ProbeBased on our in vitro results, we speculated that Mn-(DPA-
C2)2-TPPS3 might be able to function, analogously to histolog-
ical dyes, as an MRI-detectable stain with both cell perme-
ability and possible zinc dependence in intact animals. Such
a function would require that cellular uptake be able to
compete kinetically with elimination of the probe after its infu-
sion or injection into tissue. In an organism, both post-infusion
concentrations of the probe and the accessible concentrations
of labile zinc would most likely be far below those we applied
in cell culture, so uptake and zinc binding would be less favor-
able. To assess the behavior of Mn-(DPA-C2)2-TPPS3 in a true
biological environment, we therefore applied the contrast agent
by injection into live rodent brains, where cell-permeable ana-
lyte-sensitive molecular imaging agents could be particularly
important for monitoring neurobiological function and disease.
We provide compelling evidence of intracellular probe localiza-
tion in vivo, as well as indications of zinc sensitivity, which
suggest the general use of the porphyrin platform for further
applications.
RESULTS
Mn-(DPA-C2)2-TPPS3 Produces Strong, Persistent
Contrast in Injected Brains
To assess the ability of Mn-(DPA-C2)2-TPPS3 to penetrate cells
and stain living brain tissue, 5 ml of a 1 mM solution of the probe
were injected intracranially into the dorsal hippocampus of rat
subjects. Each infusion was paired with a symmetric 5 ml injec-
tion of 1 mM Mn-TPPS4 into the contralateral hemisphere, and
anesthetized animals were subsequently imaged on a 9.4 T
MRI scanner. The paired injection procedure was designed to
test whether relative staining patterns observed with the two
agents in vitro would be reproduced in vivo, while at the same
time controlling for trial-to-trial variability in experimental param-
eters such as animal positioning and radiofrequency coil tuning.
Injected rats were examined at multiple time points after contrast
agent delivery. After 2 days, strong contrast was consistently
observed in the hippocampus injected with Mn-(DPA-C2)2-
TPPS3, whereas little signal enhancement over background666 Chemistry & Biology 17, 665–673, June 25, 2010 ª2010 Elsevierwas observed on the side injected with Mn-TPPS4 (Figure 1B).
This result shows that the relatively efficient cellular contrast
induction exhibited by Mn-(DPA-C2)2-TPPS3 in vitro is repro-
duced in living brain tissue.
Rats were scanned again at 4 and 10 days after contrast agent
injection. Contrast differences between Mn-(DPA-C2)2-TPPS3
and Mn-TPPS4 injection sites remained throughout this period
(Figure 1C). MRI signal was quantified in regions of interest
(ROIs) around the injection sites. Each ROI was defined by a
1.2 mm radius sphere centered around an injection site, as
judged from images with isotropic 150 mm resolution. Measured
signal amplitudes were normalized with respect to control ROIs
near but outside the injected areas. Examination of the MRI
signal time courses graphed in Figure 1D shows that the signal
difference between Mn-(DPA-C2)2-TPPS3 and Mn-TPPS4 injec-
tion areas decayed to 50% its initial value over the 10-day
observation period, suggesting an approximately half-life of
10 days for injected Mn-(DPA-C2)2-TPPS3. A mean maximal
enhancement of 21 ± 7% (n = 7) with respect to the control
volume was observed in the Mn-(DPA-C2)2-TPPS3 infusion
ROI, whereas average MRI signal in the Mn-TPPS4 region was
slightly less intense with respect to the control, probably
because of signal dropout in the immediate vicinity of the
injection needle insertion site. Signal differences between
Mn-(DPA-C2)2-TPPS3 and Mn-TPPS4 ROIs were statistically
significant on all days (t test p = 0.006–0.027).
Persistence of the MRI signal enhancement produced by
Mn-(DPA-C2)2-TPPS3 over several days suggested that this
probe was sequestered intracellularly or tightly bound to immo-
bilized components of the tissue. To better understand the
contrasting dynamics of signal changes caused by Mn-TPPS4,
the time course of image enhancement was examined over a
short time scale after Mn-TPPS4 injection in two further animals.
Image series (see Figure S1 available online) showed that
T1-weighted contrast enhancement occurred shortly after
delivery of Mn-TPPS4, but that the signal increase dissipated
almost entirely over a period of less than two hours. Fast clear-
ance from brain has been observed previously with classical
hydrophilic MRI contrast agents such as Gd-DTPA (Liu et al.,Ltd All rights reserved
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Figure 2. Microanatomical Localization of Hippocampal MRI Contrast after Mn-(DPA-C2)2-TPPS3 Infusion
(A) Close up of MRI contrast enhancement in injected hippocampus, with Nissl-stained section (B) for comparison. The most hyperintense areas in (A) correlate
with dense Nissl-stained cell body layers in (B). Hippocampal subfields, CA1, CA3, and dentate gyrus (DG), are labeled in B for reference.
(C) Intrinsic staining visualized by transmitted light through a 100 mm section obtained from the subject imaged for (A) and (B). The field of view centers on the DG
and corresponds to the blue rectangle in (A). Scale bar = 100 mm.
(D) Close up of the area delineated by the dashed rectangle in (C), showing homogeneous yellow-brown staining in laminae of DG. Scale bar = 50 mm.
(E and F) Visualization of nuclei via DAPI fluorescence in the same section shown in (C) and (D) (equivalent fields of view).
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In Vivo MRI with a Porphyrin-Based Probe2004; Wan et al., 1991), which are thought to have a predomi-
nantly extracellular tissue distribution.
Porphyrin-Based Probe Localizes to Cell Bodies
in the Hippocampus
The spatial pattern of the contrast enhancement observed with
Mn-(DPA-C2)2-TPPS3 was examined at a microanatomical level.
Comparison of MRI and Nissl-stained histological images
(Figures 2A and 2B) revealed strong similarities and suggested
that the most hyperintense regions resolved by MRI corre-
sponded to RNA-rich structures, probably cell somata. System-
atic differences between MRI enhancements observed in the
three hippocampal subfields, CA1, CA3, and dentate gyrus
(DG), were not discernible. Further analysis of localization
patterns was aided by the optical absorbance of Mn-(DPA-C2)2-
TPPS3. In particular, 100-mm sections of injected rat brains
extracted after imaging displayed intrinsic contrast resulting
from the probe and directly reflecting its distribution in the brain.
Close-up views of a representative section (Figures 2C and 2D)
displayed a yellow-brown color that appeared most concen-
trated in laminae that were also strongly stained by the nuclear
stain 40,6-diamidino-2-phenylindole (DAPI; Figures 2E and 2F).
These results imply that MRI contrast enhancement in brain
regions injected with Mn-(DPA-C2)2-TPPS3 was largely due to
localization of the probe in cell bodies.
The intrinsic optical contrast due to injected probe was rela-
tively homogeneous in 100-mm sections (Figure 2D), suggesting
that Mn-(DPA-C2)2-TPPS3 was distributed broadly in intracellular
compartments. In addition, near the injection needle insertion
points, discrete darker colored spheroids of 5 mm in diameter
were observed under bright-field illumination of 30-mm sections
(Figure 3). Some of these spheroids corresponded to structures
also resolved by terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL staining; Figures 3E
and 3F). MRI hyperintense areas more distal from the injectionChemistry & Biology 17,sites did not exhibit TUNEL positivity. We therefore infer that
the brown TUNEL-positive puncta might be cells that had been
physically disrupted by the injection procedure and that had
acquired particularly high concentrations of the contrast agent.
Based on the absence of TUNEL-positive cells and the normal
appearance of Nissl staining throughout most of the MRI
contrast-enhanced brain regions, we conclude that the probe
had little deleterious effect on brain tissue in general and is
therefore unlikely to be strongly cytotoxic. We also noted no
serious changes to the behavior of injected rats in the home
cage environment, which provides further indication that
contrast agent delivery is not significantly harmful to the animals,
despite its relatively long retention time in the brain.
Mn-(DPA-C2)2-TPPS3 Retained in Brain Tissue
Is Primarily Cytosolic
The accumulation of Mn-(DPA-C2)2-TPPS3 in injected brain
tissue was examined directly by trace element analysis. Rats
received bilateral hippocampal infusions of 5 ml contrast agent
(n = 6) or phosphate buffered saline (PBS) vehicle control
(n = 6), and were scanned after 2 days. Immediately after MRI,
these animals were sacrificed and dissected to obtain dorsal
hippocampal tissue specimens weighing an average of 28.8 ±
1.7 mg (wet weight), each containing much of the volume of
distribution around an injection site. Samples were digested,
dried, and evaluated by flameless atomic absorption spectros-
copy (AAS) to determine the amounts of manganese present.
Excess manganese in test samples versus PBS controls was
taken to reflect the local deposition of Mn-(DPA-C2)2-TPPS3.
The mean Mn concentrations in test and control samples were
2.5 ± 0.5 and 0.44 ± 0.03 parts per million (ppm = mg/g wet
tissue), respectively. The difference of 2.1 ppm is equivalent to
approximately 40 mM contrast agent, assuming brain density of
1 g/mL, a dilution of the infusate by a factor of 25 that presumably
reflects convective dynamics during the injection, diffusion and665–673, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 667
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Figure 3. Foci of Contrast Agent Accumulation and TUNEL Positivity near an Injection Site
(A) MRI scan showing contrast enhancement around the injection site in another rat infused with Mn-(DPA-C2)2-TPPS3 in the left hippocampus.
(B) Nissl stained section corresponding to (A), showing mechanical damage due to the needle insertion (arrowhead).
(C) Intrinsic staining in a bright field view of a 30-mm section corresponding to (A) and (B), showing discrete puncta of coloration due to accumulation of the
contrast agent in the immediate proximity of the injection needle insertion site (arrowhead). Scale bar = 100 mm.
(D) Close up of the view in (C), corresponding to the dotted rectangle. Scale bar = 50 mm.
(E) TUNEL staining to visualize dead cells in the slice shown in (C). TUNEL positivity is observed only near the needle insertion site (arrowhead), but not in the rest of
the section, despite broad MRI contrast enhancement observed throughout the depicted region (cf. A).
(F) Close up of (E), showing close correspondence of TUNEL-positive foci to colored puncta shown in (D).
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In Vivo MRI with a Porphyrin-Based Probewash-out during the two day post-infusion period, and aspects
of sample preparation. Manganese concentrations from AAS
correlated closely (R = 0.87, p < 0.0001) with MRI intensities
measured from 1.2 mm-radius spherical ROIs around the infu-
sion sites (Figure 4A). The regression coefficient of 10.7% MRI
signal change per ppm Mn was combined with a reference T1
measurement from rat hippocampus (de Graaf et al., 2006) to
estimate an in vivo relaxivity of 3 mM1s1 for injected
Mn-(DPA-C2)2-TPPS3. This approximate value is somewhat
lower, but of the same order of magnitude, as the reported
relaxivity range of 6.7–8.7 mM1s1 of the contrast agent in
buffer at 4.7 T (Zhang et al., 2007). These results provide
absolute evidence of probe accumulation in injected tissue and
validate AAS as a basis for semiquantitative estimates of the
Mn-(DPA-C2)2-TPPS3 concentrations that gave rise to observed
MRI contrast enhancements.
The AAS analysis was extended to provide information about
the subcellular distribution of injected Mn-(DPA-C2)2-TPPS3.
Brain samples from an additional set of animals injected with
either Mn-(DPA-C2)2-TPPS3 or PBS were combined (n = 4 per
condition), homogenized, and fractionated to determine the
manganese content in cytosolic, nuclear, and mixed membra-
nous compartments of the tissue (Cox and Emili, 2006). Figure 4B
shows the manganese concentrations measured by AAS in each
of the three fractions. Total Mn concentrations summed across
the three intracellular fractions were lower than the average
values measured from unfractionated samples, a disparity that
we presume to reflect primarily differences in sample prepara-
tion techniques. The fact that similar, approximately 2-fold,
discrepancies were found in both test and control samples
argues against the possibility that a particularly large amount
of extracellular contrast agent was present in the samples668 Chemistry & Biology 17, 665–673, June 25, 2010 ª2010 Elsevierinjected with Mn-(DPA-C2)2-TPPS3. Data from the fractionated
samples indicate that the cytosol contained 69% of the manga-
nese found near Mn-(DPA-C2)2-TPPS3 injection sites, and 66%
of the excess manganese observed with respect to control
injections. Nuclear and membranous fractions contained 14%
and 21% of the excess Mn, respectively. The AAS data therefore
demonstrate conclusively that the injected probe entered cells,
and suggest that the contrast patterns observed by MRI arose
largely from cytosolically-localized Mn-(DPA-C2)2-TPPS3.
Mn-(DPA-C2)2-TPPS3 Stains a Zinc-Rich Brain Area
with Greater Efficiency
In addition to exploiting cell permeability of the porphyrin plat-
form, Mn-(DPA-C2)2-TPPS3 was designed to respond to labile
zinc ions; the probe exhibits zinc-dependent MRI contrast
enhancement in cells in vitro (Zhang et al., 2007). To begin
examining zinc sensitivity of Mn-(DPA-C2)2-TPPS3 in vivo, we
compared contrast due to probe injection into two brain struc-
tures known to contain differing levels of labile zinc. Areas of
the hippocampus are consistently identified as some of the
most Zn2+-rich neural structures in mammals (Nakashima and
Dyck, 2009). Reservoirs of vesicular Zn2+ have been associated
with glutamatergic synaptic transmission and may play a role in
hippocampal long term potentiation (Frederickson et al., 2005).
Although technical limitations of the injection procedure pre-
vented us from carrying out a meaningful analysis of relative
Mn-(DPA-C2)2-TPPS3 staining in hippocampal subregions, we
examined whether MRI-visualized Mn-(DPA-C2)2-TPPS3 stain-
ing in the hippocampus was more pronounced than staining in
the caudate-putamen, a region of the basal ganglia shown by
histochemical analyses to contain substantially less labile Zn2+
(Frederickson et al., 1987, 1992).Ltd All rights reserved
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Figure 4. Quantification of Manganese Content
in Injected Brain Specimens
(A) Correspondence of manganese concentrations
determined by atomic absorption spectroscopy (AAS)
with relative image signal determined by MRI for hippo-
campal specimens injected with Mn-(DPA-C2)2-TPPS3
(gray symbols, n = 12) or PBS vehicle control (white
symbols, n = 12). [Mn] values are expressed in parts
per million (ppm = mg/g wet tissue), and relative MRI signal
was determined as described in the caption to Figure 1.
A linear fit to the data gave rise to the dashed line, which
has a slopeof10.7%signal change perppmMn.The regres-
sion was highly significant with R = 0.87 and p < 0.0001.
(B) Hippocampal specimens injected with either Mn-
(DPA-C2)2-TPPS3 or PBS (each n = 4) were combined,
homogenized, and fractionated to determine the concentration of manganese in cytosolic, nuclear, and mixed membranous compartments of the tissue.
[Mn] values for each fraction were determined by AAS for test (gray) and control (white) samples, and show primarily cytosolic localization of the contrast agent.
Error bars denote standard deviations of three measurements from each sample.
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In Vivo MRI with a Porphyrin-Based ProbeAs in the hippocampus, Mn-(DPA-C2)2-TPPS3 produced clear
contrast enhancement in the caudate, whereas Mn-TPPS4 did
not (Figure 5A). Contrast observed in the caudate was relatively
featureless by comparison to enhancements observed in the
hippocampus, however, possibly reflecting the absence of
cytoarchitectonic laminae in this structure. In addition, markedly
greater MRI signal was observed after Mn-(DPA-C2)2-TPPS3
injection into the hippocampus than into the caudate-putamen
area (Figure 5B). Across six animals injected in both sites, probe
injections resulted on average in a 19.5 ± 8.5% signal increase
with respect to uninjected control ROIs in the hippocampus,
but only a 4.2 ± 2.0% increase in the caudate. In both brain
regions, differences between the signal changes produced by
Mn-(DPA-C2)2-TPPS3 and Mn-TPPS4 injection were statistically
significant (t test p = 0.02-0.04), but the mean difference
observed in the hippocampus (24 ± 10%) was >3-fold higher
than in the caudate (7.1 ± 4.1%). The weak zinc dependence
of Mn-(DPA-C2)2-TPPS3 relaxivity in solution reported previously
(Zhang et al., 2007) could not explain the results and would have
predicted a lower MRI intensity in the hippocampus with respect
to the caudate. The measurements instead support the conclu-
sion that accumulation of Mn-(DPA-C2)2-TPPS3 was more
pronounced in the hippocampus than in the caudate nucleus,
consistent with the hypothesis that this probe accumulates
more efficiently in brain areas that contain greater amounts of
labile Zn2+.
To examine further the relationship between in vivo staining
and Zn2+ availability, we combined hippocampal injection of
Mn-(DPA-C2)2-TPPS3 with pretreatment using the high-affinityA B
re
l. s
ig
na
l (%
) Mn-(DPA-
90
100
110
120
130
HP
Mn-TPPS4Mn-(DPA-C2)2
     -TPPS3
show significantly greater staining with Mn-(DPA-C2)2-TPPS3 than with the cont
the zinc-rich hippocampus than in the caudate, which contains substantially less
Chemistry & Biology 17,zinc chelator tris(2-pyridylmethyl)amine (TPA; X.Z. and S.J.L.,
unpublished data). A 4-ml dose of 1 mM TPA or vehicle was deliv-
ered to sites in opposite hemispheres, followed by 4 ml of 1 mM
probe. The relative MRI signal averaged across hippocampal
ROIs in all animals was 124 ± 8% without TPA and 109 ± 12%
with TPA. Although the difference is not statistically significant
(t test p = 0.3, n = 5), the lower image intensity observed in
the presence of TPA is compatible with the explanation that
TPA-mediated Zn2+ chelation reduced uptake of the probe,
within the limits of experimental variability across the tested
animals.
DISCUSSION
Advantages of Metalloporphyrin-Based Agents
for In Vivo Molecular Imaging
Results presented in this study highlight the advantages of met-
alloporphyrin-based MRI contrast agents for molecular imaging
in vivo. The first is cell permeability, a property for which earlier
in vitro experiments with Mn-(DPA-C2)2-TPPS3 provided only
circumstantial evidence (Zhang et al., 2007). In rat brains, the
contrast agent proved to stain cells persistently and with signif-
icantly greater efficiency than its more polar parent molecule,
Mn-TPPS4. The observed pattern of contrast enhancement
with Mn-(DPA-C2)2-TPPS3 suggests that the probe most
effectively stains neuronal cell bodies, as opposed to plexiform
layers. Correspondence between MRI intensity enhancement
and the intrinsic contrast of the probe in brain sections indicates
that preferential staining of gray matter was due directly toC2)2-TPPS3
Mn-TPPS4
CP
Figure 5. Differential Staining with Mn-(DPA-C2)2-
TPPS3 in Hippocampus and Caudate-Putamen
(A) MRI contrast visualized 2 days after injection of
Mn-(DPA-C2)2-TPPS3 and Mn-TPPS4, respectively, into
the left and right caudate-putamen of a representative
rat. The image was obtained with 150 mm cubic voxels
and TE/TR = 6/50 ms.
(B) As a preliminary test of zinc-dependent uptake of
Mn-(DPA-C2)2-TPPS3 in injected brains, relative MRI sig-
nal was quantified in hippocampal (HP) and caudate (CP)
regions of interest, near injection sites for Mn-(DPA-C2)2-
TPPS3 (gray) and Mn-TPPS4 (white). Both brain regions
rol compound, but the difference is roughly three times greater on average in
labile zinc. Error bars denote SEM for n = 6.
665–673, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 669
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In Vivo MRI with a Porphyrin-Based Probeaccumulation of Mn-(DPA-C2)2-TPPS3, rather than to differences
in apparent relaxivity of the probe in white and gray matter. The
bias for gray matter is also consistent with AAS results showing
robust accumulation of Mn-(DPA-C2)2-TPPS3 in cytosol. The
data presented in this study show that Mn-(DPA-C2)2-TPPS3
entered cells in intact brain tissue, rather than merely partitioning
into membranes or other hydrophobic environments. This
behavior indicates that the metalloporphyrin platform should
be well suited to the construction of cell-permeable molecular
imaging agents for MRI.
A second advantage of the metalloporphyrin platform for
molecular imaging is the potential for multimodal measurements
with porphyrin-based probes. In the study that presented
synthesis of Mn-(DPA-C2)2-TPPS3, we noted that the apopor-
phyrin form of this agent exhibits zinc-dependent fluorescence
(Zhang et al., 2007). Here we used the optical absorbance of
Mn-(DPA-C2)2-TPPS3 itself to determine the distribution of the
probe in post-mortem brain slices. Given the possibility, some-
times by design, that environmental factors can influence MRI
signal enhancement by a contrast agent, the ability to map
porphyrin-based probe distribution by this optical method is an
extremely important asset. In addition to facilitating quantitative
interpretation of molecular imaging results, the optical assay can
help localize probes on length scales below the resolution of
MRI. Combined MRI and histological analysis is of obvious value
for experiments in laboratory animals, and a similar approach
could also be useful for studies relating MRI contrast enhance-
ment to biopsy samples in a clinical diagnostic context.
Zinc Sensing Via Accumulation of anMRIContrast Agent
Mn-(DPA-C2)2-TPPS3 displayed evidence of zinc sensitivity in
injected rat brains. Contrast enhancement was substantially
more pronounced in the labile zinc-rich hippocampus than in
the caudate nucleus, which contains much less vesicular Zn2+.
If labile zinc were the only factor that determined localization
patterns of Mn-(DPA-C2)2-TPPS3 in the brain, the MRI results
presented here would have matched previously reported fluores-
cent and histochemical maps of zinc distribution (Frederickson
et al., 2000., Frederickson, 2003). Results from these ex vivo
techniques have shown relatively light staining in the caudate-pu-
tamen (Frederickson et al., 1987, 1992), but intense and specific
layer- and subfield-dependent staining patterns in the hippo-
campus, especially emphasizing the mossy fiber pathway from
DG to CA3 (Slomianka, 1992). Such precise results were not ob-
tained by MRI, possibly in part because of the tendency of the
probe to accumulate in cells even in the absence of zinc (Zhang
et al., 2007), perhaps compounded by disruptions after the
injection procedure itself. There was no evidence for extensive
cell disruption or death, however, so cytotoxicity is unlikely to
have been a major factor in the results. Zinc detection with Mn-
(DPA-C2)2-TPPS3 or related compounds could be improved in
the future by modifying the probe further to disfavor zinc-inde-
pendent staining, and by using experimental paradigms that
involve less invasive, more homogeneous probe delivery
methods.
Zinc-dependent contributions to the tissue accumulation of
Mn-(DPA-C2)2-TPPS3 may have arisen in part because of
charge-related effects. Mn-(DPA-C2)2-TPPS3 is anionic (2) in
the absence of analyte, but neutral or cationic (+2) when bound670 Chemistry & Biology 17, 665–673, June 25, 2010 ª2010 Elsevierto one or two Zn2+ ions, respectively. Neutral or positively
charged species are thought to be more readily imported by
cells. Mn-TPPS4 is even more negatively charged (3) than
Mn-(DPA-C2)2-TPPS3, which may account for its relatively fast
elimination from injected brain tissue. The idea of generating
contrast based on analyte-dependent transport of a molecular
imaging agent has parallels to a variety of MRI-based tracer
techniques (Lin and Koretsky, 1997; Mansson et al., 2006;
Querol and Bogdanov, 2006), but represents a sharp departure
from ion-sensitive MRI contrast mechanisms based on T1 or T2
relaxivity changes (Atanasijevic et al., 2006, 2010; Esqueda
et al., 2009; Li et al., 1999; Que and Chang, 2009). Molecular
transport in vivo is inherently complex, as well as irreversible
on a short time scale, but analyte sensing based on transport
of an agent might nevertheless have advantages over detection
based on relaxivity changes. In particular, transport-based
probes could achieve greater MRI signal changes, both because
of the possibility that their accumulation might be facilitated by
relatively small amounts of analyte (in analogy to ionophores
and transmembrane carrier proteins, for instance), and because
relatively high contrast could be developed during extended
probe infusion protocols. Owing to their cell permeability and
ability to induce robust contrast changes in living tissue, para-
magnetic metalloporphyrins may prove to be effective platforms
on which to improve and diversify probe localization-based
approaches to measuring biological targets in vivo.SIGNIFICANCE
The results in this study show that a paramagnetic metallo-
porphyrin MRI molecular imaging agent penetrates cells in
tissue and permits analysis of neural structures in living
mammalian brains, without apparent toxic side effects.
Imaging agents based on intrinsically membrane-permeable
platforms like porphyrins constitute an effective alternative
to probes formed by conjugating contrast agents to specific
cell delivery vehicles. Optical absorbance of the probe used
here, Mn-(DPA-C2)2-TPPS3, allowed MRI contrast results to
be validated by conventional post-mortem histology, illus-
trating a further advantage of porphyrin-based agents. Mn-
(DPA-C2)2-TPPS3 binds Zn
2+ ions with high affinity (Zhang
et al., 2007), and preliminary evidence of zinc-dependent
uptake of the probe was provided by comparison of staining
results obtained in brain regions containing different labile
zinc concentrations. MRI-based molecular imaging with
probes that accumulate in analyte-dependent fashion
in vivo represents a potentially generalizable approach
distinct from strategies for sensing analytes via relaxivity
changes.EXPERIMENTAL PROCEDURES
MRI Contrast Agents
Mn-(DPA-C2)2-TPPS3 was prepared and purified as previously described
(Zhang et al., 2007). Mn-TPPS4 was purchased from Frontier Scientific (Logan,
UT). Both Mn-(DPA-C2)2-TPPS3 and Mn-TPPS4 were dissolved in phosphate
buffered saline (PBS) to constitute 1 mM solutions for infusion experiments.Ltd All rights reserved
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Male Lewis rats (250–300 g) were purchased from Charles River Laboratories
(Wilmington, MA). After arrival, animals were housed and maintained on a 12 hr
light/dark cycle and permitted ad lib access to food and water. All procedures
were carried out in strict compliance with the Committee on Animal Care (CAC)
guidelines of the Massachusetts Institute of Technology.Contrast Agent Infusion
Animals were anesthetized with isoflurane (4% induction, 1%–2% mainte-
nance), shaved, and mounted in a rodent stereotaxic device (David Kopf
Instruments, Tujunga CA) before surgery. Heart rate and blood oxygenation
were continuously monitored using a pulse oximeter (Nonin Medical, Ply-
mouth, MN) during subsequent procedures. The scalp was retracted and small
holes were drilled into the skull above desired injection sites. Twenty-eight
gauge needles (Plastics One, Roanoke, VA) were lowered to the appropriate
depth through the holes. Infusion coordinates were defined with reference to
a standard atlas (Paxinos and Watson, 1998), as follows: 3 mm posterior,
2 mm lateral, and 3.4 mm ventral to bregma for the hippocampus, and
0.5 mm posterior, 3 mm lateral, and 5 mm ventral to bregma for the caudate
nucleus. At each injection site, 5 ml of either Mn-(DPA-C2)2-TPPS3 or
Mn-TPPS4 was infused using an injection pump (Cole-Parmer, Vernon Hills,
IL) operating with an infusion rate of 18 mL/h. For several experiments, an injec-
tion of 4 ml 1 mM TPA (ATRP Solutions, Pittsburgh, PA) preceded infusion of
4 ml contrast agent. TPA was dissolved to 100 mM in dimethyl sulfoxide
(DMSO) and diluted to 1 mM in PBS; vehicle controls were 1% DMSO in
PBS. After each infusion, the injection needle was held in place for 5 min to
prevent reflux before withdrawing. The scalp was sutured and in some cases
animals were scanned while still under surgical anesthesia. Further imaging
experiments were conducted after recovery of the animals. For experiments
in which conditions were paired (Mn-(DPA-C2)2-TPPS3 versus Mn-TPPS4 or
+TPA versus TPA), brain hemispheres exposed to each given condition
were alternated.MRI
MRI scans were obtained up to 10 days postinjection. Animals were anesthe-
tized with 1%–2% isoflurane and mounted into a positioning device under a
four-channel phased array radiofrequency coil (Bruker Biospin, Billerica,
MA). The animal holder was inserted into a 20 cm bore 9.4 T magnet operated
from a Bruker Biospec console, and animals were monitored with a respirom-
eter (Bruker Biospin). Data were acquired with a T1-weighted gradient echo
pulse sequence and an acceleration factor of two, with 48 reference lines for
multichannel data reconstruction. Images with 150 mm cubic voxel size were
obtained with a repetition time (TR) of 50 ms, echo time (TE) of 6 ms, field of
view (FOV) of 303 303 22.5 mm, and data matrix of 2003 200 3 150 points
(no averaging, scan time = 15.5 min); images with 753 753 300 mm voxel size
were obtained with TR = 50 ms, TE = 6 ms, FOV = 303 303 150 mm, and data
matrix of 400 3 400 3 50 points (4-fold averaging, scan time = 37.3 min).Image Analysis
Images were reconstructed in Paravision 4 (Bruker Biospin) and transformed
to AFNI data format; data conversion and further image processing were
carried out using AFNI (Cox, 1996). Brains were segmented away from non-
brain matter and ROIs were defined as spheres of 1.2 mm radius around
injection sites identified in the images. Mean signal intensity in each ROI was
computed by averaging over voxels. Signal in each ROI was normalized by
the mean signal recorded in an uninjected control region with the same dorso-
ventral and rostrocaudal coordinates as the injection site. Control regions had
equivalent size to the injected ROIs and were located in primary or secondary
somatosensory cortex, paired with hippocampal or caudate injection sites,
respectively. Local normalization by signal in the control regions served to
eliminate systematic effects of image inhomogeneity on the measured signal
intensities. Statistical analyses and further data display were carried out using
Excel (Microsoft, Redmond, WA) and Kaleidagraph (Synergy Software,
Reading, PA). Unless otherwise noted, error margins reported in the text reflect
standard errors of the mean (SEM) over multiple measurements.Chemistry & Biology 17,Histology
After the final scanning sessions, rats were sacrificed by isoflurane overdose
and perfused with PBS, followed by 4% buffered formaldehyde solution.
Brains were removed and stored in 4% formaldehyde for several days. Thin
brain slices (40 mm for Nissl staining and 30 mm for TUNEL staining) were cut
with a Leica VT1200 microtome (Leica Microsystems, Wetzlar, Germany).
For Nissl staining, brain slices were mounted on gelatin coated slides
(SouthernBiotech Associates, Birmingham, AL) and stained with cresyl violet
following a common procedure (Paxinos and Watson, 1998). For TUNEL stain-
ing, brain slices were rinsed twice with PBS and dried on the gelatin coated
slides. Mounted slices were processed with 50 ml TUNEL reaction solution
supplied as part of the Roche Applied Science (Mannheim, Germany) In Situ
Death Detection Kit, TMR red. After 1 hr of incubation at 37C, brain slices
were rinsed three times with PBS and treated with mounting medium including
DAPI (Vector Laboratories, Burlingame, CA). Photomicrographs from these
slides were acquired using an Olympus BX50WI epifluorescence microscope
(Olympus America, Center Valley, PA) equipped with a Spot RT741 digital
camera (Diagnostic Instruments, Sterling Heights, MI).
Trace Element Analysis
For analysis of manganese content in injected rat hippocampus, 12 animals
were infused bilaterally with 5 ml of 1 mM Mn-(DPA-C2)2-TPPS3 or PBS vehicle
control solutions and scanned after 2 days with 150 mm isotropic resolution,
using methods described above. Immediately after MRI, these rats were
sacrificed and decapitated. Brains were removed quickly and dorsal hippo-
campal segments were dissected. Brain samples were placed immediately
on dry ice and stored in a 80C freezer. Twenty-four samples weighing
16–47 mg and containing the injection volumes were analyzed to determine
total manganese content. Tissue samples were processed according to a
published protocol (Pera and Harder, 1977), beginning with digestion in nitric
acid at 40C, followed by evaporation to near dryness. Dried, digested
samples were resuspended in 1 N HCl (2 mL) and again heated to near dryness;
this procedure was repeated twice. Dried samples were finally dissolved in 1 ml
0.1 N HCl for manganese analysis by flameless atomic absorption spectropho-
tometry (AAS). Measurements were carried out on an AAnalyst 600 instrument
from Perkin-Elmer (Waltham, MA). Calibration was carried out using manga-
nese aqueous standards prepared in 5% nitric acid from a commercial stan-
dard solution (Perkin-Elmer Pure AS Standard). The calibration curve for Mn
was linear over the range from 1 to 200 mg/L, and the mean Mn concentration
determined from vehicle control samples (0.44 ± 0.09 ppm) was comparable to
that in a published precedent (Cosan et al., 2006).
Eight additional hippocampal samples weighing 19–36 mg were analyzed
to determine the distribution of manganese among cytosolic, nuclear, and
mixed membranous fractions. Brain specimens were fractionated following
a published procedure (Cox and Emili, 2006). Briefly, tissue samples were
weighed and washed with ice-cold 250-STMDPS buffer (50 mM Tris-HCl,
pH 7.4, 250 mM sucrose, 5 mM MgCl2, 1 mM dithiothreitol [DTT], 1 mM phenyl-
methanesulfonyl fluoride [PMSF], 25 mg/mL spermine, and 25 mg/mL spermi-
dine) and then submerged in 250-STMDPS buffer. After 15 strokes in a Dounce
homogenizer, the extract was centrifuged at 800 3 g for 15 min and the pellet
was used to prepare the nuclear fraction. The 8003 g supernatant was centri-
fuged again at 100,000 3 g in a swinging-bucket rotor ultracentrifuge for 1 hr.
The supernatant from this separation constituted the cytosolic fraction; the re-
maining sedimented material was further processed to isolate membrane-
containing components. The pellet was resuspended in 0.5 ml of membrane
extraction buffer (20 mM Tris-HCl, pH 7.8, 0.4 M NaCl, 15% glycerol, 1 mM
DTT, 1 mM PMSF and 1.5% Triton X-100) and incubated for 1 hr with gentle
rocking, followed by centrifugation for 30 min at 9000 3 g. The membranous
fraction (plasma membrane, Golgi bodies, vesicles, endoplasmic reticulum)
was considered to be the supernatant from this separation. The pellet was
homogenized with a single stroke in a Dounce homogenizer in 2M-TMDPS
buffer (50 mM Tris–HCl, pH 7.4, 2 M sucrose, 5 mM MgCl2, 1 mM DTT,
1mM PMSF, 25 mg/mL spermine, and 25 mg/mL spermidine) and further frac-
tionated at 80003 g for 35 min. The pellet from this final centrifugation was re-
suspended in nuclear extraction buffer (20 mM HEPES, pH 7.9, 1.5 mM MgCl2,
0.5 M NaCl, 0.2 mM EDTA and 20%, glycerol) and used as the nuclear fraction.
Manganese concentrations in all fractions were determined by AAS, as
described above.665–673, June 25, 2010 ª2010 Elsevier Ltd All rights reserved 671
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Relaxivity of Mn-(DPA-C2)2-TPPS3 in injected rat brain was estimated using
the approximation that r1 z(DI/I)(Dc)
1(T1)
1, which is valid under strong
T1-weighting conditions like those applied here (TR = 50 ms), where r1 is the
longitudinal relaxivity, DI/I is the fractional MRI signal change for a given
difference in probe concentration Dc, and T1 is the initial longitudinal relaxation
time. (DI/I)(Dc)1 was given by the slope of a linear fit to the plot of AAS
measurements versus MRI signal enhancements (Figure 4A): 10.7% MRI
signal change per ppm Mn, equivalent to 5.88 fractional MRI change per
mM. A T1 value of 2.06 s for rat hippocampus at 9.4 T was obtained from
the literature (de Graaf et al., 2006).SUPPLEMENTAL INFORMATION
Supplemental Information includes one figure and can be found with this
article online at doi:10.1016/j.chembiol.2010.05.009.
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